SNY analyst estimates
Sanofi (SNY) analyst ratings, the average price target and its range, and every firm's latest call.
SNY analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Jul 8, 2026 | Morgan Stanley | Sanofi price target lowered to $49 from $52 at Morgan Stanley | $49.00 |
| May 1, 2026 | Morgan Stanley | Sanofi downgraded to Equal Weight from Overweight at Morgan Stanley | $52.00 |
| Apr 20, 2026 | BNP Paribas | Sanofi downgraded to Neutral from Outperform at BNP Paribas | $50.00 |
| Jun 2, 2025 | Morgan Stanley | Sanofi resumed with an Equal Weight at Morgan Stanley | $56.00 |
| Sep 10, 2024 | Berenberg Bank | Sanofi price target raised to $64 from $56 at Berenberg | $64.00 |
| Jul 26, 2024 | Argus Research | Sanofi-Aventis (SNY) PT Raised to $60 at Argus | $60.00 |
| Apr 3, 2024 | Argus Research | Sanofi-Aventis (SNY) PT Lowered to $55 at Argus, 'BUY as FDA reviews Dupixent for COPD' | $55.00 |
| Dec 21, 2022 | Barclays | Sanofi confirms to Bloomberg Zantac settlement in California | $48.07 |
- 14 firms rate SNY: 10 buy, 3 hold, 1 sell.
- The average price target is $49.00 from 1 analysts, from $49.00 to $49.00.
Updated 2026-11-02 17:14 UTC